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Abstract
Objective—To determine the motor phenotype of LRRK2 G2019S mutation carriers
Background—LRRK2 mutation carriers were previously reported to manifest the tremor-dominant
(TD) motor phenotype, which has been associated with slower motor progression and less cognitive
impairment compared to the postural instability gait difficulty (PIGD) phenotype.
Design—Cross sectional observational study
Setting—13 movement disorders centers
Participants—925 Early Onset Parkinson Disease (EOPD) cases defined as age at onset (AAO)
!50.
Main Outcome Measures—LRRK2 mutation status and PD motor phenotype: TD or PIGD
Methods—Demographic information, family history of PD (FHPD), and the Unified Parkinson
Disease Rating Scale (UPDRS) were collected on all participants. DNA samples were genotyped for
LRRK2 mutations (G2019S, I2020T, R1441C and Y1699C). Logistic regression was used to examine
associations of G2019S mutation status with motor phenotype adjusting for disease duration,
Ashkenazi Jewish (AJ) ancestry, levodopa dose, and FHPD.
Results—34 cases (3.7%) (14 previously reported) were G2019S carriers. No other mutations were
found. Carriers were more likely to be AJ (55.9% vs. 11.9% p<0.001), but did not significantly differ
in any other demographic or disease characteristics. Carriers had a lower tremor score (p=0.026) and
were more likely to have a PIGD phenotype (92.3% vs. 58.9% p=0.003). The association of the
G2019S mutation with PIGD phenotype remained after controlling for disease duration and AJ (OR=
17.7, p< 0.001).
Conclusion—EOPD G2019S LRRK2 carriers are more likely to manifest the PIGD phenotype,
which may have implications for disease course.
Introduction
Mutations in LRRK2 (Leucine-Rich Repeat Kinase-2) (PARK8) are associated with both
sporadic and familial Parkinson’s disease (PD). The most frequently reported LRRK2 mutation,
G2019S (nt. 2877510G"A) is found in up to 1% of sporadic and 4% of familial PD cases
worldwide.1 Furthermore, up to 39% of Northern African Arab2 and 18.3% of Ashkenazi
Jewish (AJ) 3, 4 PD cases carry the mutation. We and others have shown that the frequency of
LRRK2 mutations is similar in early onset PD (EOPD) and late-onset PD; 1, 5 however, only
small series of LRRK2 mutation carriers with EOPD have been described.3, 6–8
LRRK2 related parkinsonism is associated with good response to treatment with levodopa and
dopamine agonists, but may be complicated by dyskinesia.1 While the presentation of
LRRK2 related PD is heterogeneous,9–11 the largest study to date of LRRK2 carriers suggested
an association between LRRK2 mutations and the tremor dominant (TD) motor phenotype.1
However, in that study, the participants’ Unified Parkinson’s Disease Rating Scale (UPDRS)
12 was not available. Given the potentially favorable prognosis that is associated with TD PD,
13 we tested this hypothesis on a large sample of EOPD cases with available UPDRS performed
by movement disorders specialists.
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We determined whether mutation status is associated with a specific motor phenotype (TD
versus postural instability and gait difficulty (PIGD).
Methods
Subjects
PD probands with AAO !50 (n = 925) were recruited from 13 sites in the Core-PD study.14
Institutional review boards at all participating sites approved the protocols and consent
procedures. Two hundred forty-five probands were previously recruited in the Genetic
Epidemiology of PD (GEPD) study between 1998 and 2003 and have been previously
described.3 Additional probands (n=680) were recruited from 2004 until 2008 based on AAO!
50 years and a score # 24 on the Mini-mental State Exam (MMSE15, 16, 17), a requirement
introduced to ensure that a reliable history could be obtained. Demographic information, a
UPDRS12 in the “on” state, completed by a movement disorders specialist, a validated family
history interview of first-degree relatives18 and the MMSE were obtained at a single visit. A
blood sample for DNA extraction was sent to the NINDS Human Genetics Resource Center
DNA and Cell Line Repository (http://ccr.coriell.org). All examiners were unaware of the
genetic status of the participants. All probands were asked about Jewish ancestry, and the 680
probands recruited in the Core-PD study were asked specifically about Ashkenazi Jewish
descent, however since 90% of Jews in the United States are Ashkenazi, we considered all
Jews AJ.19 Participants were considered AJ only if all four grandparents were AJ.
Probands were classified into motor subtypes based on previously described methodology:
tremor dominant (TD), postural instability and gait difficulty (PIGD) or intermediate.20 Based
on the UPDRS, we computed a mean score of eight tremor items (self report of tremor, chin
tremor, right and left arm tremor, right and left leg tremor and right and left arm action tremor
on examination), as well as a mean score of five PIGD items (self report of falling, freezing
and walking difficulty. Gait and postural instability on examination). A ratio of tremor score
divided by PIGD score was then computed. TD was defined as ratio # 1.5 and PIGD as ! 1.
Probands with a ratio between 1–1.5 were classified as intermediate. Individuals with missing
data on any of the required items were not classified as TD or PIGD.
Molecular Genetic Analysis
Genotyping of LRRK2 mutations of 245 probands in the GEPD study has been described
previously,3 using Matrix-Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF)
mass spectrometry (Sequenom). An additional 193 DNA samples from individuals recruited
in CORE PD were genotyped using the same assay. We analyzed all samples for mutations
G2019S, I2020T, R1441C and Y1699C and also assessed the frequency of 2 rare LRRK2
variants (I1122V, L1114L).
DNA samples from the remainder of the probands recruited in CORE PD (n=487) were
analyzed using a previously described genotyping chip 21 (Asper Biotech, Tartu, Estonia).
Thirty individuals who carried G2019S detected by MALDI-TOF were also examined using
the genotyping chip without knowledge of the MALDI-TOF results and were confirmed. In
addition to G2019S, all samples analyzed by the genotyping chip were also examined for the
mutations R1441C, I2020T and Y1699C.
Statistical analyses
Student t-test, chi-square, and Fisher exact tests were used as appropriate to compare
continuous and categorical variables between G2019S carriers and non-carriers. Univariate
logistic regression models were constructed to examine the association between LRRK2
G2019S mutation status (dependent variable) and Jewish ancestry, total daily dose of levodopa,
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family history of PD in a first degree relative, AAO), disease duration, age at exam and PIGD
or TD subtypes. A multivariate logistic regression model was then constructed including all
significant associations. Disease duration was added to the model because of the expected
association between disease duration and disease severity.
Since disease duration is highly associated with severity of motor and cognitive symptoms in
PD,22 we performed additional analyses comparing probands with longer vs. shorter disease
duration (tertiles) to determine the effect of disease duration on the association of G2019S and
motor subtype. We repeated the analysis on all probands with disease duration less than 5 years.
In a separate analysis, we included only probands who were not taking levodopa, regardless
of disease duration. Given the high proportion of AJ heritage among LRRK2 carriers in previous
studies,3 analyses were repeated separately for all 126 AJ probands. To assess for a potential
confounding effect of parkin, we conducted analyses excluding all parkin mutation carriers,
In a separate analysis, we excluded probands who underwent surgery (pallidotomy,




Among 925 probands tested, 34 (3.7%) carried a G2019S mutation. Fourteen (41.2%) of these
were previously reported.3 One carrier, who was AJ, was a G2019S homozygote. None of the
other pathogenic mutations (R1441C, Y1699C and I2020T) was found. Carriers and non-
carriers had similar AAO (range: 13–50 years), disease duration, age at examination, UPDRS-
III and MMSE scores. Carriers were more likely to report AJ ancestry (55.9% vs. 11.9%,
p<0.001), but not more likely to report a first-degree relative with PD than non-carriers. Carriers
were more likely to manifest the PIGD phenotype and less likely to be of the TD phenotype.
Complete UPDRS scores required to compute PIGD and tremor scores were available on 691
probands, 26 of whom were carriers. Demographic and disease characteristics of carriers and
non-carriers with complete UPDRS (n=691) are presented in Table 1.
The remaining probands were missing either the entire UPDRS (n=35), or items on the UPDRS-
II (n=134) or UPDRS-III (n=65). When motor phenotype was computed based only on the
UPDRS-III (n=825, G2019S carriers = 29) carrier status was again associated with higher
prevalence of PIGD after adjustment for AJ ancestry and disease duration (OR 16.4; 95%
confidence interval 2.1–127.8, p=0.008).
Because of the strong association between PIGD phenotype and G2019S carrier status we
compared demographic and disease characteristics of PIGD and TD probands (excluding the
intermediate probands, n=92) (Table 2). PIGD probands were older, had a longer disease
duration, higher UPDRS-III scores and daily levodopa doses, and lower MMSE scores than
TD cases. When we compared PIGD G2019S carriers (n=24) with non-carrier PIGD probands
(n=392) there was no significant difference between groups in demographic and disease
severity parameters. We did not compare TD or intermediate G2019S carriers to non-carriers
because we found only one carrier in each of these motor phenotype groups.
In univariate logistic regression models G2019S was significantly associated only with AJ
ancestry and PIGD motor phenotype. In the final multivariate logistic regression model
including 691 cases, the association of G2019S carrier status with PIGD motor phenotype
remained, after adjustment for AJ ancestry and disease duration (Table 3). Total daily dose of
levodopa, AAO, and family history of PD were not associated with G2019S mutation status
in either the univariate or multivariate model. After adjustment for disease duration, the
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association between PIGD and G2019S remained when analyses were performed in 81 AJ and
610 non-AJ separately (AJ: OR= 9.9; 95% CI: 1.8–53.0, p= 0.008. Non AJ: all G2019S carriers
were PIGD. Fisher exact p-value=0.004), confirming that the association is not dependent on
ethnic background.
Because of the association of PIGD with longer disease duration (Table 2) we examined the
relationship of PIGD with disease duration separately in G2019S carriers and non-carriers. For
this purpose we stratified the probands into tertiles of disease duration (!6, 6–13, #13 years).
Among non-carriers, the prevalence of the PIGD phenotype increased with disease duration
from 41.3% (107/259), to 61.8% (135/215), to 78.5% (150/191). In contrast, among carriers
of the G2019S mutation, all but two subjects, both in the lowest tertile, had the PIGD phenotype,
so that the prevalence in the three duration tertiles was 81.8% (9/11), 100% (8/8), 100% (7/7).
A consequence of this pattern is that the association between PIGD and mutation status was
restricted to the shortest disease duration tertile (OR=15; 95% CI: 2.4–92.9, p=0.004).
When only probands with disease duration of five years or less were analyzed (n=212, 9 of
whom were G2019S carriers), adjusting for AJ ancestry in a logistic regression model, the
association was significant (OR =15.7; 95% CI: 2.1–119.6, p=0.008). In a separate analysis,
when only probands who were not taking levodopa were assessed (n= 188, 6 of whom G2019S
carriers) the association held, (Fisher exact p=0.043). In an analysis excluding all parkin
carriers, including 28 homozygotes/compound heterozygotes and 37 heterozygotes, the
association between PIGD and G2019S status was unchanged (OR: 17.6, 95%CI: 3.8–82.8,
p<0.001). Of note, there was one G2019S carrier who also carried a heterozygous mutation in
the parkin gene. The association between carrier status and PIGD held after excluding 150
probands who underwent brain surgery (pallidotomy, thalamotomy, fetal transplantation or
DBS) prior to the current evaluation (OR: 5.3, 95%CI 1.5–18.7, p<0.009)
Comment
Previous reports have suggested that LRRK2 mutations may be associated with tremor in PD.
1, 23, 24 In fact, the protein encoded by LRRK2 was named dardarin – a term derived from
dardara, the Basque word for tremor.25 The largest LRRK2 sample to date found that the core
features of carriers included asymmetrical, tremor predominant parkinsonism,1 however the
UPDRS scores were not available and TD and PIGD scores were not calculated. Here, when
we tested the association on a large EOPD sample evaluated with the UPDRS, the G2019S
mutation carriers have lower tremor scores on the UPDRS, and are more likely to manifest the
PIGD motor phenotype than non carriers. Because the PIGD phenotype is associated with
longer disease duration, we examined whether the greater prevalence of PIGD in carriers in
our study was due longer disease duration. Duration was similar in carriers and non-carriers,
allowing us to reject this explanation. LRRK2 G2019S and PIGD phenotype were significantly
associated in AJ and non-AJ groups separately, supporting the generalizability of the findings.
To our knowledge, only one other study of 187 EOPD cases computed the TD and PIGD motor
subtype scores.26 None of the subjects included in that study carried the G2019S mutation.
Fifty percent of the cases were PIGD, similar to the non-carriers in our study. While only EOPD
cases were included in this study, limiting generalizability, the effect of age on the presence
of PIGD are not as apparent in this sample (mean age 52.3) allowing us to detect a difference
among carriers versus non-carriers of G2019S.
Previous studies of late onset PD that did not define groups by genotype have shown that PD
patients with the PIGD phenotype have a more severe form of PD than those with the TD
phenotype, as manifested by a higher proportion of patients with dementia and greater severity
as defined by higher UPDRS scores.22 While most studies of PIGD evaluated PD cases with
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AAO #50, one study in which 50% (n=200) of the participants had an AAO! 50 showed a
significant association between PIGD phenotype and disease severity (defined by Hoehn and
Yahr scale) and poor cognition.27 In general, the PIGD phenotype has been associated with a
faster rate of cognitive decline,28 and is found to be over represented in demented PD patients
and in patients with dementia with Lewy bodies.29
In our study, PIGD was associated with more severe clinical course than TD, as indicated by
a higher UPDRS-III score, higher levodopa dose and lower MMSE score. However, although
G2019S carriers were more likely than non-carriers to have the PIGD motor phenotype, carriers
and non-carriers were indistinguishable in terms each of these measures of clinical course.
Whether the adverse prognosis associated with PIGD applies to G2019S carriers with a PIGD
phenotype is unknown.
The major limitation of this study is that it is cross-sectional, and the effect of G2019S on
disease progression cannot be assessed directly. While 925 probands were examined, the
UPDRS-III was available on 825 subjects, and complete UPDRS, required for motor
phenotyping20, was available on 691. Given that our results were similar when applied to the
entire dataset and to those who had the complete UPDRS evaluation, this is not likely to be a
significant confounder.
Another potential limitation of our study is that only 34 G2019S carriers were identified.
Therefore, larger samples with broader representation of different ethnic groups would be
valuable. The only cognitive assessment obtained, the MMSE, detected cognitive differences
between PIGD and TD probands, but may be too insensitive to detect subtle differences
between G2019S carriers and non-carriers. Since only G2019S mutation carriers were detected,
these results may not be generalized to all LRRK2 mutations. However, the G2019S probably
accounts for 90% of the known pathogenic mutations.1
In order to further test the association between G2019S carrier status and motor phenotype a
long term follow up on a large sample of carriers is required. A longitudinal follow up including
a detailed motor and cognitive exam will confirm the prognosis of mutation carriers.
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Table 1
Comparison of demographic and clinical features between 691 G2019S carriers and non-carriers on whom
complete UPDRS was available
LRRK2 G2019S
carriers (n=26) LRRK2 non-carriers (n=665) Significance
Age at onset (years) 42.9 (5.0) 41.7 (6.7) NS
Age at examination (years) 52.7 (8.4) 52.1 (8.7) NS
Disease duration (years) 9.8 (7.8) 10.4 (7.6) NS
Education (years) 15.6 (3.3) 15.6 (2.8) NS
UPDRS-III 19.7 (13.7) 20.5 (11.7) NS
Levodopa daily dose (mg) 556 (624) 471 (492) NS
MMSE score 29.1 (1.6) 29.1(1.6) NS
Gender (% females) 46.2% (12) 38.2% (254) NS
Ashkenazi Jewish Ancestry (%) 57.7% (15) 10.1% (67) p<0.001
First degree family history of PD (%
positive)
20.8% (5) 15.3% (99) NS
First degree family history of PD in
AJ (% positive)
21.4% (n=3) 15.2 (n=10) NS
First degree family history of AD (%
positive)
0% 4.9% NS
Report of hallucinations1 3.8% (1) 7.0% (46) NS
Asymmetric onset (%)2 88.5% (23) 94.0% (614) NS
Rest tremor as presenting symptom
(%)2
44.0%(11) 41.5(271) NS
Mean tremor score 3 2 (2.1) 3.4(3.8) p=0.0264
Mean PIGD score3 4.4 (3.2) 3.4(3.3) NS
PIGD phenotype 92.3% (24) 58.9% (392) P=0.003
TD phenotype 3.8% (1) 27.4% (182) p=0.003
Values are mean (standard deviation) or percent (number)
1
score of 2 or above on the 2nd question (thought disorder question) on the UPRDS-I questionnaire
2
Presenting symptoms as reported by the participants
3
The sum of points received for tremor or PIGD items on the UPDRS respectively
4
The 0.8 point difference corresponds to 30% difference
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Table 2
Comparison of demographic and clinical features between 599 PIGD and TD cases with complete UPDRS
scores1
PIGD (n=416) TD (n=183) Significance
G2019S carriers 5.8% (24) 0.5% (1) p=0.002
AAO (years) 41.8 (6.5) 42.1 (6.8) NS
Age (years) 54.1 (8.9) 49.7 (7.4) p<0.001
Disease duration (years) 12.3 (8.0) 7.5 (6.0) p<0.001
Education (years) 15.5 (2.9) 15.7 (2.8) NS
MMSE 28.9 (1.9) 29.4 (1.1) p= 0.002
UPDRS-III 22.1 (13.0) 18.6 (8.9) p<0.001
Daily levodopa dose (mg) 578 (518) 280 (344) p<0.001
Gender (% female) 42.1% (175) 31.7% (158) p<0.001
Ashkenazi Jewish 11.1% (46) 14.2% (26) NS
Family history of PD 16.4% (67) 12.6% (22) NS
Report of hallucinations2 9.7% (40) 2.2% (4) p<0.001
1
excluding 92 intermediate cases, only one of which is a G2019S carrier
2
score of 2 or above on the 2nd question (thought disorder question) on the UPRDS-I questionnaire
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